Quarterly report · Q1
4361.TEDINET S100T7MO
Period2023-12-01 → 2024-02-29
Filed2024-04-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.0bn | 2023-12-01 → 2024-02-29 | Cons. | Net sales |
| Revenue | ¥8.6bn | 2022-12-01 → 2023-11-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.1bn | 2022-12-01 → 2023-02-28 | Cons. | Net sales |
| Operating income | ¥68m | 2023-12-01 → 2024-02-29 | Cons. | Operating income |
| Operating income | ¥47m | 2022-12-01 → 2023-02-28 | Cons. | Operating income |
| Ordinary income | ¥67m | 2023-12-01 → 2024-02-29 | Cons. | Ordinary income |
| Ordinary income | ¥345m | 2022-12-01 → 2023-11-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥46m | 2022-12-01 → 2023-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥67m | 2023-12-01 → 2024-02-29 | Cons. | Income before income taxes |
| Profit before tax | ¥46m | 2022-12-01 → 2023-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥50m | 2023-12-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥256m | 2022-12-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41m | 2022-12-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥50m | 2023-12-01 → 2024-02-29 | Cons. | Profit loss |
| Net income | ¥41m | 2022-12-01 → 2023-02-28 | Cons. | Profit loss |
| Total assets | ¥8.1bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2023-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.4bn | at 2024-02-29 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2023-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥2.6bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥2.6bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2023-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥906m | at 2024-02-29 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2023-11-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥40.79 | 2023-12-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.88 | 2022-12-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.77 | 2022-12-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.5% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.1% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-02-29 | ¥60m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-02-29 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-02-29 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-02-29 | ¥8m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-02-29 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-02-29 | ¥68m |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue | 2022-12-01 → 2023-02-28 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | revenue external | 2022-12-01 → 2023-02-28 | ¥2.0bn |
| jpcrp040300-q1r_E01006-000Pharmaceutical Productsreportable segment | segment profit | 2022-12-01 → 2023-02-28 | ¥39m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue | 2022-12-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | revenue external | 2022-12-01 → 2023-02-28 | ¥10m |
| jpcrp040300-q1r_E01006-000Real Estate Leasingreportable segment | segment profit | 2022-12-01 → 2023-02-28 | ¥8m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-12-01 → 2023-02-28 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-12-01 → 2023-02-28 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-12-01 → 2023-02-28 | ¥47m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 333
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)株主としての権利内容に制限のない、標準となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)同上 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)川口化学工業株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都千代田区内神田２丁目８番４号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |